Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vigil Neuroscience, Inc.

< Previous 1 2 Next >
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Present at Stifel 2023 CNS Days
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience to Present at Upcoming Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Tickers VIGL
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.